Loading...
XNYS
ABBV
Market cap370bUSD
Mar 31, Last price  
209.57USD
1D
2.08%
1Q
17.93%
Jan 2017
234.67%
IPO
501.69%
Name

Abbvie Inc

Chart & Performance

D1W1MN
P/E
86.66
P/S
6.58
EPS
2.42
Div Yield, %
2.96%
Shrs. gr., 5y
3.62%
Rev. gr., 5y
11.11%
Revenues
56.33b
+3.71%
14,214,196,00015,638,000,00017,443,951,00018,380,000,00018,790,000,00019,960,000,00022,859,000,00025,638,000,00028,216,000,00032,753,000,00033,266,000,00045,804,000,00056,197,000,00058,054,000,00054,318,000,00056,334,000,000
Net income
4.28b
-12.03%
4,636,515,0004,178,000,0003,433,128,0005,275,000,0004,128,000,0001,774,000,0005,144,000,0005,953,000,0005,309,000,0005,687,000,0007,882,000,0004,616,000,00011,542,000,00011,836,000,0004,863,000,0004,278,000,000
CFO
18.81b
-17.66%
5,367,336,0004,976,000,0006,246,960,0006,345,000,0006,267,000,0003,549,000,0007,535,000,0007,041,000,0009,960,000,00013,427,000,00013,324,000,00017,588,000,00022,777,000,00024,943,000,00022,839,000,00018,806,000,000
Dividend
Jan 15, 20251.64 USD/sh
Earnings
Apr 24, 2025

Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
URL
https://www.abbvie.com/
IPO date
Jan 02, 2013
Employees
50,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
56,334,000
3.71%
54,318,000
-6.44%
58,054,000
3.30%
Cost of revenue
29,695,000
41,772,000
39,184,000
Unusual Expense (Income)
NOPBT
26,639,000
12,546,000
18,870,000
NOPBT Margin
47.29%
23.10%
32.50%
Operating Taxes
(570,000)
1,377,000
1,632,000
Tax Rate
10.98%
8.65%
NOPAT
27,209,000
11,169,000
17,238,000
Net income
4,278,000
-12.03%
4,863,000
-58.91%
11,836,000
2.55%
Dividends
(11,025,000)
(10,539,000)
(10,043,000)
Dividend yield
3.50%
3.84%
3.50%
Proceeds from repurchase of equity
(1,708,000)
(1,972,000)
(1,225,000)
BB yield
0.54%
0.72%
0.43%
Debt
Debt current
6,804,000
7,191,000
4,136,000
Long-term debt
60,340,000
53,718,000
59,906,000
Deferred revenue
Other long-term liabilities
30,129,000
33,517,000
30,655,000
Net debt
61,310,000
47,789,000
54,572,000
Cash flow
Cash from operating activities
18,806,000
22,839,000
24,943,000
CAPEX
(777,000)
(695,000)
Cash from investing activities
(20,820,000)
(2,009,000)
(623,000)
Cash from financing activities
(5,211,000)
(17,222,000)
(24,803,000)
FCF
33,427,000
11,115,000
17,413,000
Balance
Cash
5,555,000
12,816,000
9,229,000
Long term investments
279,000
304,000
241,000
Excess cash
3,017,300
10,404,100
6,567,300
Stockholders' equity
(9,768,000)
(3,250,000)
2,636,000
Invested Capital
110,405,000
107,311,000
108,577,000
ROIC
24.99%
10.35%
15.05%
ROCE
25.81%
12.06%
16.64%
EV
Common stock shares outstanding
1,773,000
1,773,000
1,778,000
Price
177.70
14.67%
154.97
-4.11%
161.61
19.36%
Market cap
315,062,100
14.67%
274,761,810
-4.38%
287,342,580
19.42%
EV
376,411,100
322,587,810
341,947,580
EBITDA
35,025,000
21,244,000
27,337,000
EV/EBITDA
10.75
15.18
12.51
Interest
2,808,000
2,224,000
2,230,000
Interest/NOPBT
10.54%
17.73%
11.82%